Cancer metastasis: A search for therapeutic inhibition

Cancer Investigation

Volumn 16, Issue 4, 1998, Pages 279-290

  Dimitroff, Charles J ^a   Sharma, Amarnath ^a   Bernacki, Ralph J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0031922428     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809039778     Document Type: Review

References (108)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1:571-573, 1889.
2. Fidler L, Kripke M: Metastasis results from pre-existing variant cells within a malignant tumor. Science 197:893-895, 1977.
3. Talmadge J, Wolman S, Fidler I. Evidence for the clonal origin of spontaneous metastasis. Science 217:361-363, 1982.
4. Price J, Aukerman S, Fidler I: Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 46:5172-5178, 1986.
5. Fidler I, Talmadge J. Evidence that intravenously derived murine pulmonary metastases can originate from the expansion of a single tumor cell. Cancer Res 46:5167-5171, 1986.
6. Hart I, Fidler I: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 41:1281-1287, 1981.
7. Morikawa K, Walker S, Jessup M, et al: In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48:1943-1948, 1988.
8. Morikawa K, Walker S, Nakajima S-P, et al: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48:6863-6871, 1988.
9. Folkman J, Watson K, Ingber D, et al: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989.
10. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1:27-31, 1995.
11. Folkman J, Klagsbrun M: Angiogenic factors. Science 235:442-447, 1987.
12. Pepper M, Belin D, Montesano R, et al: Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 111:743-755, 1990.
13. Liotta L, Steeg P, Stetler-Stevenson W: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336, 1991.
14. Ray J, Stetler-Stevenson W: The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7:2062-2072, 1994.
15. Sloane B, Moin K, Krepela E, et al: Cathepsin B and its endogenous inhibitors. Their role in tumor malignancy. Cancer Metastasis Rev 9:333-352, 1990.
16. Pyke C, Ralfkiaer E, Huhtala P, et al: Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52:1336-1341, 1992.
17. Polette M, Clavel C, Cockett M, et al: Detection and localization of matrix metalloproteinases and their tissue inhibitor in breast pathology. Invasion Metastasis 13:31-37, 1993.
18. Kawame H, Toshida K, Ohsaki A, et al: Stromelysin-3 mRNA expression and malignancy: comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res 13:2319-2324, 1993.
19. Vanveldhuizen P, Sadasivan R, Cherian R, et al: Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312:8-11, 1996.
20. Hackel C, Czerniak B, Ayala A, et al: Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrossarcoma. Cancer 79:53-58, 1997.
21. Yoshizaki T, Sato H, Maruyama Y, et al: Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 19:139-144, 1997.
22. Garbisa S, Pozzatti R, Muschel R, et al: Secretion of type IV collagenolytic protease and metastatic phenotype: Induction of transfection with c-H-ras but not c-H-ras plus Ad2-E1a. Cancer Res 47:1523-1528, 1987.
23. Dave B, Singh R, Fidler I, et al: Chromosome 14 alteration is associated with increased collagenase expression and the metastatic potential of murine melanomas. Cancer Genet Cytogenet 92:66-72, 1996.
24. Lee K, Rha S, Kim S, et al: Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metastasis 14:512-519, 1996.
25. Bernhard E, Muschel R, Hughes E: Mr 92,000 gelatinase releases correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 50:3872-3877, 1990.
26. Sreenath T, Matrisian L, Stetler-Stevenson W, et al: Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 52:4942-4947, 1992.
27. Alizadeh H, Ma D, Berman M, et al: Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 14:449-158, 1995.
28. Hagiya Y, Fukao H, Ueshima S, et al: Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line. Clin Chim Acta 253:37-50, 1996.
29. Vleminckx K, Vakaet L, Mareel M, et al: Genetic manipulation of E-cadhedrin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66:107-119, 1991.
30. Jothy S, Munro S, LeDuy L, et al: Adhesion or anti-adhesion in cancer: what matters more? Cancer Metastasis Rev 14:363-376, 1995.
31. Smythe W, LeBel E, Bavaria J, et al: Integrin expression in nonsmall cell carcinoma of the lung. Cancer Metastasis Rev 14:229-239, 1995.
32. Ziober B, Lin C, Kramer R: Laminin-binding integrins in tumor progression and metastasis. Sem Cancer Biol 7:119-128, 1996.
33. Akiyama S, Olden K, Yamada K: Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14:173-189, 1995.
34. Allen D, Connolly N, Biggart J: Mucin profiles in ulcerative colitis with dysplasia and carcinoma. Histopathology 13:399-411, 1988.
35. Kim Y, Gum J, Brockhausen I: Mucin glycoproteins in neoplasia. Glycocon J 13:693-707, 1996.
36. Ota T, Matsui T, Kohno H, et al: CD44 participates in tumor cell adhesion to endothelial cells in the experimental metastasis process in B16BL6 melanoma cells. Anticancer Res 15(4): 1215-1219, 1996.
37. Iida J, Meijne A, Knutson J, et al: Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol 7:155-162, 1996.
38. Benchimol S, Fuks A, Jothy S, et al: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57:327-334, 1989.
39. Skrincosky D, Allen H, Bernacki RJ: Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin-binding glycoprotein. Cancer Res 53:2667-2675, 1993.
40. Hofmann N, Rudy W, Zoller M, et al. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51:5292-5297, 1991.
41. Jessup J, Patrick A, Toth C, et al: Carcinoembryonic antigen: enhancement of liver colonization through retention of human colorectal carcinoma cells. Br J Cancer 67:463-470, 1993.
42. Saitoh O, Wang W, Lotan R, et al. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 267:5700-5711, 1992.
43. Inohara H, Raz A: Functional evidence that cell surface galectin-3 mediated homotypic cell adhesion. Cancer Res 55:3267-3271, 1995.
44. Lauri D, Needham L, Martin-Padura I, et al: Tumor cell adhesion to endothelial cells: endothelial leukocyte adhesion molecule-1 as an inducible adhesive receptor specific for colon carcinoma. J Natl Cancer Inst 83:1321-1324, 1991.
45. Raz A, Lotan R: Endogenous galactoside-binding lectins: A new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 6:433-452, 1987.
46. Irimura T, Nakamori S, Matsushita Y, et al: Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-LeX antigens. Semin Cancer Biol 4:319-324, 1993.
47. Brown P, Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 6:967-974, 1995.
48. Wang X, Fu X, Brown P, et al: Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like model in nude mice. Cancer Res 54:4726-4728, 1994.
49. Davies B, Brown P, East N, et al: A synthetic matrix metalloproteinase Inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087-2091, 1993.
50. Chirvi R, Garofalo A, Crimmin M, et al: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460-464, 1994.
51. Macaulay V, O'Byrne K, Saunders M, et al: Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions. Br J Cancer 71:11, 1995 (abstract).
52. Drummond A, Beckett P, Bone E, et al: BB-2516: An orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 36:100, 1995 (abstract).
53. Brown P, Baillet C: Tumour marker levels during marimastat therapy. Lancet 348:263-264, 1996.
54. Santos O, Daniels R, McDermott C, et al: Anti-tumor effects with synthetic matrix metalloproteinase inhibitors AG3319 and AG3340. Proc Am Assoc Cancer Res 37:90, 1996 (abstract).
55. Sloane B, Moin K, Krepela E, et al: Cathepsin B and its endogenous inhibitors: The role in tumor malignancy. Cancer Metastasis Rev 9:333-352, 1990.
56. Leto G, Pizzolanti G, Tumminello F, et al: Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin A (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors. In Vivo 8:231-236, 1994.
57. Tumminello F, Bernacki RJ, Gebbia N, et al: Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications. Med Res Rev 13:199-208, 1993.
58. Akiyama S, Olden K, Yamada K: Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14:173-189, 1995.
59. Humphries M, Yamada K, Olden K: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233:466-470, 1986.
60. Fujii H, Komazawa H, Mori H, et al: Antimetastatic activities of synthetic ARG-GLY-ASP-SER (RGDS) and ARG-LEU-ASP-SER (RLDS) peptide analogues and their inhibitory mechanisms. Biol Pharmacol Bull 18:1681-1688, 1995.
61. Morla A, Zhang Z, Ruoslahtl E: Superfibronectin is a functionally distinct form of fibronectin. Nature 367:193-196, 1994.
62. Pasqualini R, Bourdoulos S, Koivunen E, et al: A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nature Medicine 2:1197-1203, 1996.
63. Kobayashi H, Matsunaga K, Oguchi Y: Antimetastatic effects of PSK Krestin, a protein bound polysaccharide obtained from basidiomycetes: An overview. Cancer Epidemiol Biometr Prev 4:275-281, 1995.
64. Matsunaga K, Ohhara M, Oguchi Y, et al. Antimetastatic effect of PSK, a protein-bound polysaccharide against the B16-BL6 mouse melanoma. Invasion Metastasis 16:27-38, 1996.
65. Oguchi H, Toyokuni T, Dean B, et al: Effect of lactose derivatives on metastatic potential of B16 melanoma cells. Cancer Commun 2:311-316, 1990.
66. Pienta K, Naik H, Akhtar A, et al: Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87:348-353, 1995.
67. Platt D, Raz A: Modulation of the lung colonization of B16-F10 melanoma cells by citrus pectin. J Natl Cancer Inst 84:438-442, 1992.
68. Glinsky G, Mossine V, Price J, et al: Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs. Clin Exp Metastasis 14:253-267, 1996.
69. Glinsky G, Price J, Glinsky V, et al: Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 56:5319-5324, 1996.
70. Kijima-Suda I, Miyamoto Y, Toyoshima S: Inhibition of experimental pulmonary metastasis of mouse colon adenocarcinoma 26 sublines by a sialic acid: Nucleoside conjugate having sialyltransferase inhibiting activity. Cancer Res 46:858-862, 1986.
71. Wagner H, Thomas P, Wolf B, et al: Inhibition of sialic acid incorporation prevents hepatic metastases. Arch Surg 125:351-354, 1990.
72. Harvey B, Toth C, Wagner H, et al: Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Res 52:1775-1779, 1992.
73. Ikeda K, Nagao Y, Achiwa K: Synthesis of sialic acid-containing nucleotide sugars: CMP-sialic acid analogs. Carbohydr Res 224:123-131, 1992.
74. Vaghefi M, Bernacki RJ, Hennen W, et al: Synthesis of certain nucleoside methylenediphosphonate sugars as potential inhibitors of glycosyltransferases. J Med Chem 30:1391-1399, 1987.
75. Woynarowska B, Wikiel H, Sharma M, et al: Inhibition of human ovarian carcinoma cell- and hexosaminidase-mediated degradation of extracellular matrix by sugar analogs. Anticancer Res 12:161-166, 1992.
76. Sharma M, Bernacki RJ, Paul B, et al: Fluorinated carbohydrates as potential plasma membrane modifiers. Synthesis of 4- and 6-fluoro derivatives of 2-acetamido-2-deoxy-D-hexopyranoses. Carbohydr Res 198:205-221, 1990.
77. Atsumi S, Nosaka C, Ochi Y, et al: Inhibition of experimental metastasis by an alpha-glucosidase inhibitor, 1,6-epi-cyclophellitol. Cancer Res 53:4896-4899, 1993.
78. Dennis J, Laferte S: Tumor cell surface carbohydrate and the metastatic phenotype. Cancer Metastasis Rev 5:185-204, 1987.
79. Dennis W: Effects of swainsonine and ployinosinic: polycytidylic acid on murine tumor cell growth and metastasis. Cancer Res 46:5131-5136, 1986.
80. Humphries M, Matsumoto K, White S, et al: Inhibition of experimental metastasis by castanospermine in mice: blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Res 46:5215-5122, 1986.
81. Newton S, White S, Humphries M, et al: Swainsonine inhibition of spontaneous metastasis. J Natl Cancer Inst 81:1024-1028, 1989.
82. Goss P, Baptiste J, Fernandes B, et al: A phase I study of swainsonine in patients with advanced malignancies. Cancer Res 54:1450-1457, 1994.
83. Bernacki RJ, Niedbala M, Korytnyk W: Glycosidases in cancer and invasion. Cancer Metastasis Rev 4:81-102, 1985.
84. Li R, Ladisch S: Abrogation of shedding of immunosuppressive neuroblastoma gangliosides. Cancer Res 56:4602-4605, 1996.
85. Inokuchi J, Jimbo M, Momosaki K, et al: Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res 50:6731-6737, 1990.
86. Inokuchi J, Jimbo M, Kumamoto Y, et al: Expression of ganglioside GM3 and H-2 antigens in clones with different metastatic and growth potentials isolated from Lewis lung carcinoma (3LL) cell line. Clin Exp Metastasis 11:27-36, 1993.
87. Woynarowska B, Skrincosky D, Haag A, et al: Inhibition of lectin mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 269:22797-22803, 1994.
88. Woynarowska B, Dimitroff CJ, Sharma M, et al: Inhibition of human colon HT-29 carcinoma cell adhesion by a 4-fluoro-glucosamine analog. Glycocon J 13:663-674, 1996.
89. Dimitroff CJ, Woynarowska B, Mazurchuk M, et al: Development of a colon tumor metastasis model in nude mice to assess the antimetastatic activity of sugar analogs using magnetic resonance imaging. Glycocon J 12:397, 1995 (abstract).
90. Bernacki R, Woynarowska B, Dimitroff CJ, et al: Inhibition of human colon carcinoma cell adhesion and homotypic aggregation by a 4-fluoro-glucosamine analog. Glycocon J 12:396, 1995 (abstract).
91. Okoshi H, Hakomori S, Nisar M, et al: Cell membrane signaling as target in cancer therapy H: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation. Cancer Res 51:6019-6024, 1991.
92. Park Y, Hakomori S, Kawa S, et al: Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: Cell membrane signaling as a target in cancer therapy III. Cancer Res 54:2213-2237, 1994.
93. Kohn E, Liotta L: Molecular insights into cancer invasion. Strategies for prevention and intervention. Cancer Res 55:1856-1862, 1995.
94. Kohn E, Liotta L: L651582, a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 82:54-60, 1990.
95. Kohn E, Jacobs W, Kim Y, et al: Calcium influx regulates matrix metalloproteinase-2 (72kDa type IV collagenase, gelatinase A) expression. J Biol Chem 269:21505-21511, 1994.
96. Kohn E, Alessandro R, Spoonster J, et al: Angiogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 92:1307-1311, 1995.
97. Kohn E, Sandeen M, Liotta L: In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 52:3208-3212, 1992.
98. Kohn E, Reed E, Sarosy G, et al: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56:569-573, 1996.
99. Gorman R, Bunting S, Miller O: Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13:377-386, 1977.
100. Honn K, Ciccone B, Skoff A: Prostacyclin: a potent antimetastatic agent. Science 212:1270-1272, 1981.
101. Constantini V, Fuschotti P, Allegrucci M, et al: Platelet-tumor cell interaction: Effect of prostacyclin and a synthetic analog on metastasis formation. Cancer Chemother Pharmacal 22:289-293, 1988.
102. Tang D, Grossi I, Tnag K, et al: Inhibition of TPA and 12(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: Rationale for their antimetastatic effects. Int J Cancer 60:418-125, 1995.
103. Schirner M, Lichtner R, Schneider M: The stable prostacyclin analogue cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3rat mammary carcinoma. Clin Exp Metastasis 12(1):24-30, 1994.
104. Schirner M, Schneider M: Rodent model of systemic mammary tumor disease by surgical removal of the spontaneously metastasizing SMT2A mammary carcinoma: Inhibitory effect of the stable prostacyclin analogue cicaprost on occult metastases. Int J Cancer 62:205-209, 1995.
105. Sharma A, Bernacki RJ: Ovarian cancer patients with high CA-125 but no symptoms-should anti-angiogenic treatments be considered? Oncol Res 9:53-54, 1997.
106. Fearon E, Volgelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
107. Gallinger S, Vivona A, Odze R, et al: Somatic APC and K-ras codon 12 mutations in periampullary adenomas and carcinomas from familial adenomatous polyposis patients. Oncogene 10(9):1875-1878, 1995.
108. Walsh N, Qizilbash A, Banerje R, et al: Biliary neoplasia in Gardner's syndrome. Arch Pathol Lab Med 111:76-77, 1987.